High-resolution Magic Angle Spinning 1H MRS in Prostate Cancer

Overview

Journal NMR Biomed

Publisher Wiley

Date 2013 Mar 27

PMID 23529951

Citations 13

Authors

Emily A Decelle

Leo L Cheng

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is the most frequently diagnosed malignancy in men worldwide, largely as a result of the increased use of the annual serum prostate-specific antigen (PSA) screening test for detection. PSA screening has saved lives, but it has also resulted in the overtreatment of many patients with PCa because of a limited ability to accurately localize and characterize PCa lesions through imaging. High-resolution magic angle spinning (HRMAS) (1)H MRS has proven to be a strong potential clinical tool for PCa diagnosis and prognosis. The HRMAS technique allows valuable metabolic information to be obtained from ex vivo intact tissue samples and also enables the performance of histopathology on the same tissue specimens. Studies have found that the quantification of individual metabolite levels and metabolite ratios, as well as metabolomic profiles, shows strong potential to improve accuracy in PCa detection, diagnosis and monitoring. Ex vivo HRMAS is also a valuable tool for the interpretation of in vivo results, including the localization of tumors, and thus has the potential to improve in vivo diagnostic tests used in the clinic. Here, we primarily review publications of HRMAS (1)H MRS and its use for the study of intact human prostate tissue.

Citing Articles

Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer.

Ravikanth Reddy R, Jagannathan N Indian J Urol. 2022; 38(2):99-109.

PMID: 35400867 PMC: 8992727. DOI: 10.4103/iju.iju_416_21.

Absolute choline tissue concentration mapping for prostate cancer localization and characterization using 3D H MRSI without water-signal suppression.

Tayari N, Wright A, Heerschap A Magn Reson Med. 2021; 87(2):561-573.

PMID: 34554604 PMC: 9290642. DOI: 10.1002/mrm.29012.

Metabolism of prostate cancer by magnetic resonance spectroscopy (MRS).

Sharma U, Jagannathan N Biophys Rev. 2020; 12(5):1163-1173.

PMID: 32918707 PMC: 7575675. DOI: 10.1007/s12551-020-00758-6.

Effectiveness of a muticomponent workout program integrated in an evidence based multimodal program in hyperfrail elderly patients: POWERAGING randomized clinical trial protocol.

Gonzalez-Sanchez M, Cuesta-Vargas A, Del Mar Rodriguez Gonzalez M, Caro E, Nunez G, Galan-Mercant A BMC Geriatr. 2019; 19(1):171.

PMID: 31226936 PMC: 6588921. DOI: 10.1186/s12877-019-1188-x.

Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer.

Ma X, Lv K, Sheng J, Yu Y, Pang P, Xu M Oncol Lett. 2019; 17(3):3077-3084.

PMID: 30867737 PMC: 6396180. DOI: 10.3892/ol.2019.9988.

References

Stenman K, Stattin P, Stenlund H, Riklund K, Grobner G, Bergh A . H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples. Biomark Insights. 2011; 6:39-47. PMC: 3076017. DOI: 10.4137/BMI.S6794. View

Cheng L, Wu C, Smith M, Gonzalez R . Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett. 2001; 494(1-2):112-6. DOI: 10.1016/s0014-5793(01)02329-8. View

Bertilsson H, Angelsen A, Viset T, Skogseth H, Tessem M, Halgunset J . A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy. Prostate. 2010; 71(5):461-9. DOI: 10.1002/pros.21260. View

Swanson M, Vigneron D, Tabatabai Z, Males R, Schmitt L, Carroll P . Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003; 50(5):944-54. DOI: 10.1002/mrm.10614. View

Burns M, Taylor J, Wu C, Zepeda A, Bielecki A, Cory D . Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. Magn Reson Med. 2005; 54(1):34-42. DOI: 10.1002/mrm.20523. View

Wu C, Jordan K, Ratai E, Sheng J, Adkins C, DeFeo E . Metabolomic imaging for human prostate cancer detection. Sci Transl Med. 2010; 2(16):16ra8. PMC: 2857699. DOI: 10.1126/scitranslmed.3000513. View

Cheng L, Lean C, Bogdanova A, Wright Jr S, Ackerman J, Brady T . Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med. 1996; 36(5):653-8. DOI: 10.1002/mrm.1910360502. View

Burns M, He W, Wu C, Cheng L . Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat. 2004; 3(6):591-8. DOI: 10.1177/153303460400300609. View

Swanson M, Keshari K, Tabatabai Z, Simko J, Shinohara K, Carroll P . Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008; 60(1):33-40. PMC: 2643975. DOI: 10.1002/mrm.21647. View

10.

Franklin R, Feng P, Milon B, Desouki M, Singh K, Kajdacsy-Balla A . hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer. 2005; 4:32. PMC: 1243239. DOI: 10.1186/1476-4598-4-32. View

11.

Fowler A, Pappas A, Holder J, Finkbeiner A, DALRYMPLE G, Mullins M . Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn Reson Med. 1992; 25(1):140-7. DOI: 10.1002/mrm.1910250114. View

12.

Santos C, Kurhanewicz J, Tabatabai Z, Simko J, Keshari K, Gbegnon A . Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. 2009; 23(4):391-8. PMC: 2891902. DOI: 10.1002/nbm.1474. View

13.

Bertilsson H, Tessem M, Flatberg A, Viset T, Gribbestad I, Angelsen A . Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples. Clin Cancer Res. 2012; 18(12):3261-9. DOI: 10.1158/1078-0432.CCR-11-2929. View

14.

DeFeo E, Cheng L . Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol Cancer Res Treat. 2010; 9(4):381-91. DOI: 10.1177/153303461000900407. View

15.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

16.

Mountford C, Saunders J, May G, Holmes K, Williams P, Fox R . Classification of human tumours by high-resolution magnetic resonance spectroscopy. Lancet. 1986; 1(8482):651-3. DOI: 10.1016/s0140-6736(86)91727-7. View

17.

Cheng L, CHANG I, Louis D, Gonzalez R . Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998; 58(9):1825-32. View

18.

Fossel E, Carr J, McDonagh J . Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med. 1986; 315(22):1369-76. DOI: 10.1056/NEJM198611273152201. View

19.

Smith R, Litwin M, Lu Y, Zetter B . Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat Med. 1995; 1(10):1040-5. DOI: 10.1038/nm1095-1040. View

20.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-32. PMC: 3260132. DOI: 10.1093/jnci/djr500. View